[go: up one dir, main page]

EA200800785A1 - 4-арил-1,4-дигидро-3(2н)-изохинолиноны и 4-арил-1,2,3,4-тетрагидроизохинолины в качестве ингибиторов igf-1r и в качестве фармакологического средства в тест-системах, фармацевтическая композиция и изделие на их основе и способ лечения заболеваний, опосредованных igf-1 рецептором - Google Patents

4-арил-1,4-дигидро-3(2н)-изохинолиноны и 4-арил-1,2,3,4-тетрагидроизохинолины в качестве ингибиторов igf-1r и в качестве фармакологического средства в тест-системах, фармацевтическая композиция и изделие на их основе и способ лечения заболеваний, опосредованных igf-1 рецептором

Info

Publication number
EA200800785A1
EA200800785A1 EA200800785A EA200800785A EA200800785A1 EA 200800785 A1 EA200800785 A1 EA 200800785A1 EA 200800785 A EA200800785 A EA 200800785A EA 200800785 A EA200800785 A EA 200800785A EA 200800785 A1 EA200800785 A1 EA 200800785A1
Authority
EA
Eurasian Patent Office
Prior art keywords
aryl
igf
receptor
izohinolinoniny
tatarstan
Prior art date
Application number
EA200800785A
Other languages
English (en)
Inventor
Ян Гунцингер
Курт Леандер
Original Assignee
Аналитикон С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аналитикон С.А. filed Critical Аналитикон С.А.
Publication of EA200800785A1 publication Critical patent/EA200800785A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Синтезированы соединения формулы (I). Обнаружено, что они регулируют понижающим образом или ингибируют экспрессию или функцию рецептора IGF-1.
EA200800785A 2005-09-09 2006-09-08 4-арил-1,4-дигидро-3(2н)-изохинолиноны и 4-арил-1,2,3,4-тетрагидроизохинолины в качестве ингибиторов igf-1r и в качестве фармакологического средства в тест-системах, фармацевтическая композиция и изделие на их основе и способ лечения заболеваний, опосредованных igf-1 рецептором EA200800785A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2005002701 2005-09-09
PCT/IB2006/002473 WO2007029106A1 (en) 2005-09-09 2006-09-08 Isoquinolines as igf-1r inhibitors

Publications (1)

Publication Number Publication Date
EA200800785A1 true EA200800785A1 (ru) 2008-08-29

Family

ID=36350070

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800785A EA200800785A1 (ru) 2005-09-09 2006-09-08 4-арил-1,4-дигидро-3(2н)-изохинолиноны и 4-арил-1,2,3,4-тетрагидроизохинолины в качестве ингибиторов igf-1r и в качестве фармакологического средства в тест-системах, фармацевтическая композиция и изделие на их основе и способ лечения заболеваний, опосредованных igf-1 рецептором

Country Status (18)

Country Link
US (1) US8044067B2 (ru)
EP (1) EP1931636B1 (ru)
JP (1) JP2009507819A (ru)
KR (1) KR20080042897A (ru)
CN (1) CN101258130B (ru)
AT (1) ATE505457T1 (ru)
AU (1) AU2006288846B2 (ru)
BR (1) BRPI0616732A2 (ru)
CA (1) CA2621836C (ru)
DE (1) DE602006021327D1 (ru)
DK (1) DK1931636T3 (ru)
EA (1) EA200800785A1 (ru)
ES (1) ES2364673T3 (ru)
IL (1) IL189883A (ru)
NO (1) NO20081207L (ru)
NZ (1) NZ566524A (ru)
WO (1) WO2007029106A1 (ru)
ZA (1) ZA200801875B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130005733A1 (en) 2010-03-09 2013-01-03 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2012106556A2 (en) 2011-02-02 2012-08-09 Amgen Inc. Methods and compositons relating to inhibition of igf-1r
WO2012143879A1 (en) * 2011-04-21 2012-10-26 Piramal Healthcare Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
US9700619B2 (en) 2011-11-11 2017-07-11 Duke University Combination drug therapy for the treatment of solid tumors
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
CN104672136B (zh) * 2013-11-30 2017-01-25 沈阳药科大学 1‑取代菲基‑n‑烷基(酰基)‑6,7‑二甲氧基‑1,2,3,4‑四氢异喹啉衍生物及其制备方法和用途
WO2017129763A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
US12398151B2 (en) 2019-03-19 2025-08-26 Suvalent Therapeutics, Inc. Sumo inhibitor compounds and uses thereof
CN114456184B (zh) * 2022-02-21 2023-08-22 南华大学附属第一医院 一种3-芳基异喹啉衍生物及其制备与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080065707A (ko) * 1999-11-03 2008-07-14 에이엠알 테크놀로지, 인크. 4-페닐-치환 테트라히드로이소퀴놀린, 및 노르에피네프린과도파민과 세로토닌의 재흡수를 차단하기 위한 이의 용도
SE0203746D0 (sv) * 2002-12-18 2002-12-18 Karolinska Innovations Ab New compounds
CA2555745C (en) * 2004-03-12 2011-05-31 Analytecon S.A. Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors

Also Published As

Publication number Publication date
US20090099229A1 (en) 2009-04-16
CN101258130B (zh) 2012-11-28
JP2009507819A (ja) 2009-02-26
CA2621836A1 (en) 2007-03-15
US8044067B2 (en) 2011-10-25
IL189883A0 (en) 2008-11-03
NZ566524A (en) 2011-01-28
ES2364673T3 (es) 2011-09-12
WO2007029106A1 (en) 2007-03-15
HK1115500A1 (en) 2008-11-28
ZA200801875B (en) 2009-08-26
KR20080042897A (ko) 2008-05-15
AU2006288846B2 (en) 2011-08-18
EP1931636A1 (en) 2008-06-18
CN101258130A (zh) 2008-09-03
IL189883A (en) 2012-07-31
AU2006288846A1 (en) 2007-03-15
BRPI0616732A2 (pt) 2013-01-01
DK1931636T3 (da) 2011-07-25
CA2621836C (en) 2013-11-12
EP1931636B1 (en) 2011-04-13
NO20081207L (no) 2008-05-27
DE602006021327D1 (de) 2011-05-26
ATE505457T1 (de) 2011-04-15

Similar Documents

Publication Publication Date Title
NL300933I2 (nl) Letermovir
BRPI0417543A (pt) quinolinas úteis no tratamento de doença cardiovascular
EA200802213A1 (ru) Способы лечения заболеваний крови
ATE440087T1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
NO20054404L (no) 5,7-Diaminopyrazolo [4,3-D] Pyrimidiner Anvendelige ved behandling av of Hypertensjon
ECSP056111A (es) Derivados de 2-acilamino-4-feniltiazol, su preparación y aplicación en terapeutica
NO20054082L (no) Pyrazol`1,5-A! 1,3,5! triazinderivater som kannabinoidreseptorligander
CY1114095T1 (el) Μυκητοκτονες συνθεσεις
WO2007038571A3 (en) Prolyl hydroxylase antagonists
NO20055516L (no) Kannabinoidreceptorligander og anvendelser derav
BRPI0413973A (pt) compostos
EA200602196A1 (ru) Производные пиразола, композиции, содержащие эти соединения, и способы применения
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
CY1109808T1 (el) Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α
ATE334967T1 (de) Pestizide pyridincarbonsäureamidderivate
MY141972A (en) Biaryloxymethylarenecarboxylic acids
NO20062256L (no) Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
EA200800785A1 (ru) 4-арил-1,4-дигидро-3(2н)-изохинолиноны и 4-арил-1,2,3,4-тетрагидроизохинолины в качестве ингибиторов igf-1r и в качестве фармакологического средства в тест-системах, фармацевтическая композиция и изделие на их основе и способ лечения заболеваний, опосредованных igf-1 рецептором
SE0200844D0 (sv) Chemical compounds
ATE476419T1 (de) Isochinolinon-kaliumkanalinhibitoren
BR0316763A (pt) Compostos de sais sulfÈnicos eficazes em fotoiniciadores catiÈnicos multifuncionais, composição e processo
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
ATE335739T1 (de) Cak inhibitoren und deren verwendungen
TW200633977A (en) Novel process for the manufacture of 3-pyrrolidin-2-yl-propionic acid derivatives